CD40/CD40L expression and its prognostic value in cervical cancer
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRAS DIVULG CIENTIFICA
Autores
Citação
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.56, article ID e13047, 8p, 2023
Resumo
CD40, a member of the tumor necrosis factor receptor (TNFR) family, is known to be involved in immune system regulation, acting as a costimulatory molecule, and in antitumor responses against cancer cells. It is a protein that is expressed in different types of cells, including immune cells and cancer cells (e.g., cervical cancer, breast cancer, melanoma). In this study, we investigated CD40/CD40L transcriptional and protein levels in cervical cancer cell lines and tumors. Higher CD40 expression was observed in cervical cancer cell lines derived from squamous cell carcinomas than from adenocarcinomas. Search of CD40/CD40L expression in cervical cancer tissues in public data sets revealed that about 83% of squamous cell carcinomas express CD40 compared to other cervical tumor subtypes. Moreover, expression of CD40 and CD40L in squamous cervical carcinomas is associated with better overall survival. Therefore, these proteins could be explored as prognostic markers in cervical cancers.
Palavras-chave
CD40, CD40L, Cervical cancer, SiHa, HeLa
Referências
- Altenburg A, 1999, J IMMUNOL, V162, P4140
- Argiriadi MA, 2019, BMC MOL CELL BIOL, V20, DOI 10.1186/s12860-019-0213-4
- Bereznaya N. M., 2007, Experimental Oncology, V29, P2
- Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386
- Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
- Chatzigeorgiou A, 2009, BIOFACTORS, V35, P474, DOI 10.1002/biof.62
- Denfeld RW, 1996, EUR J IMMUNOL, V26, P2329, DOI 10.1002/eji.1830261009
- Dugger K, 2009, SEMIN IMMUNOL, V21, P289, DOI 10.1016/j.smim.2009.06.002
- Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000
- Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
- Hakkarainen T, 2003, CLIN CANCER RES, V9, P619
- Hill SC, 2005, J IMMUNOL, V174, P41, DOI 10.4049/jimmunol.174.1.41
- Huang Q, 2011, CANCER EPIDEMIOL, V35, P388, DOI 10.1016/j.canep.2010.12.004
- Huang Q, 2011, MED ONCOL, V28, P781, DOI 10.1007/s12032-010-9538-8
- Karlsson M, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh2169
- Lánczky A, 2021, J MED INTERNET RES, V23, DOI 10.2196/27633
- Laniewski P, 2020, NPJ PRECIS ONCOL, V4, DOI 10.1038/s41698-020-0126-x
- Li DK, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12037
- Lin-Lee YC, 2006, J BIOL CHEM, V281, P18878, DOI 10.1074/jbc.M513315200
- Liu HB, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2014195118
- Ma DY, 2009, SEMIN IMMUNOL, V21, P265, DOI 10.1016/j.smim.2009.05.010
- Moerman-Herzog A, 2015, CLIN VACCINE IMMUNOL, V22, P850, DOI 10.1128/CVI.00223-15
- Richards DM, 2020, HUM VACC IMMUNOTHER, V16, P377, DOI 10.1080/21645515.2019.1653744
- Sabel MS, 2000, CANCER IMMUNOL IMMUN, V49, P101, DOI 10.1007/s002620050608
- Tong AW, 2003, CANCER GENE THER, V10, P1, DOI 10.1038/sj.cgt.7700527
- Tong AW, 2001, CLIN CANCER RES, V7, P691
- Ünver N, 2020, TURK J BIOL, V44, P73, DOI 10.3906/biy-1912-21
- Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280
- Vonderheide RH, 2007, CLIN CANCER RES, V13, P1083, DOI 10.1158/1078-0432.CCR-06-1893
- Weiss JM, 2014, HUM IMMUNOL, V75, P614, DOI 10.1016/j.humimm.2014.04.018
- World Health Organization (WHO), 2022, Fact sheet
- Yan C, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01442-3
- Yan C, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01366-y
- Zhang BK, 2013, IMMUNOL LETT, V153, P58, DOI 10.1016/j.imlet.2013.07.005